BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ferreira NN, de Oliveira Junior E, Granja S, Boni FI, Ferreira LMB, Cury BSF, Santos LCR, Reis RM, Lima EM, Baltazar F, Gremião MPD. Nose-to-brain co-delivery of drugs for glioblastoma treatment using nanostructured system. Int J Pharm 2021;603:120714. [PMID: 34015380 DOI: 10.1016/j.ijpharm.2021.120714] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Agnihotri TG, Jadhav GS, Sahu B, Jain A. Recent trends of bioconjugated nanomedicines through nose-to-brain delivery for neurological disorders. Drug Deliv Transl Res 2022;12:3104-20. [PMID: 35570262 DOI: 10.1007/s13346-022-01173-y] [Reference Citation Analysis]
2 Mardikasari SA, Budai-Szűcs M, Orosz L, Burián K, Csóka I, Katona G. Development of Thermoresponsive-Gel-Matrix-Embedded Amoxicillin Trihydrate-Loaded Bovine Serum Albumin Nanoparticles for Local Intranasal Therapy. Gels 2022;8. [PMID: 36421572 DOI: 10.3390/gels8110750] [Reference Citation Analysis]
3 Mardikasari SA, Sipos B, Csóka I, Katona G. Nasal route for antibiotics delivery: Advances, challenges and future opportunities applying the quality by design concepts. Journal of Drug Delivery Science and Technology 2022;77:103887. [DOI: 10.1016/j.jddst.2022.103887] [Reference Citation Analysis]
4 Barzegar Behrooz A, Talaie Z, Syahir A. Nanotechnology-Based Combinatorial Anti-Glioblastoma Therapies: Moving from Terminal to Treatable. Pharmaceutics 2022;14:1697. [DOI: 10.3390/pharmaceutics14081697] [Reference Citation Analysis]
5 Fekrirad Z, Barzegar Behrooz A, Ghaemi S, Khosrojerdi A, Zarepour A, Zarrabi A, Arefian E, Ghavami S. Immunology Meets Bioengineering: Improving the Effectiveness of Glioblastoma Immunotherapy. Cancers 2022;14:3698. [DOI: 10.3390/cancers14153698] [Reference Citation Analysis]
6 Madani F, Esnaashari SS, Webster TJ, Khosravani M, Adabi M. Polymeric nanoparticles for drug delivery in glioblastoma: State of the art and future perspectives. J Control Release 2022;349:649-61. [PMID: 35878729 DOI: 10.1016/j.jconrel.2022.07.023] [Reference Citation Analysis]
7 Miranda RR, Ferreira NN, Souza EE, Lins PMP, Ferreira LMB, Krüger A, Cardoso VMO, Durigon EL, Wrenger C, Zucolotto V. Modulating Fingolimod (FTY720) Anti-SARS-CoV-2 Activity Using a PLGA-Based Drug Delivery System. ACS Appl Bio Mater 2022. [PMID: 35732506 DOI: 10.1021/acsabm.2c00349] [Reference Citation Analysis]
8 El Kheir W, Marcos B, Virgilio N, Paquette B, Faucheux N, Lauzon M. Drug Delivery Systems in the Development of Novel Strategies for Glioblastoma Treatment. Pharmaceutics 2022;14:1189. [DOI: 10.3390/pharmaceutics14061189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Wu SY, Wu FG, Chen X. Antibody-Incorporated Nanomedicines for Cancer Therapy. Adv Mater 2022;:e2109210. [PMID: 35142395 DOI: 10.1002/adma.202109210] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Zha S, Wong KL, All AH. Intranasal Delivery of Functionalized Polymeric Nanomaterials to the Brain. Adv Healthc Mater 2022;11:e2102610. [PMID: 35166052 DOI: 10.1002/adhm.202102610] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
11 Watchorn J, Clasky AJ, Prakash G, Johnston IAE, Chen PZ, Gu FX. Untangling Mucosal Drug Delivery: Engineering, Designing, and Testing Nanoparticles to Overcome the Mucus Barrier. ACS Biomater Sci Eng 2022;8:1396-426. [PMID: 35294187 DOI: 10.1021/acsbiomaterials.2c00047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
12 Yang K, Wu Z, Zhang H, Zhang N, Wu W, Wang Z, Dai Z, Zhang X, Zhang L, Peng Y, Ye W, Zeng W, Liu Z, Cheng Q. Glioma targeted therapy: insight into future of molecular approaches. Mol Cancer 2022;21:39. [PMID: 35135556 DOI: 10.1186/s12943-022-01513-z] [Cited by in Crossref: 50] [Cited by in F6Publishing: 58] [Article Influence: 50.0] [Reference Citation Analysis]
13 Chen TC, da Fonseca CO, Levin D, Schönthal AH. The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers. Pharmaceutics 2021;13:2167. [PMID: 34959448 DOI: 10.3390/pharmaceutics13122167] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Al Ojaimi Y, Blin T, Lamamy J, Gracia M, Pitiot A, Denevault-Sabourin C, Joubert N, Pouget JP, Gouilleux-Gruart V, Heuzé-Vourc'h N, Lanznaster D, Poty S, Sécher T. Therapeutic antibodies - natural and pathological barriers and strategies to overcome them. Pharmacol Ther 2021;:108022. [PMID: 34687769 DOI: 10.1016/j.pharmthera.2021.108022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]